Copyright
©The Author(s) 2017.
World J Gastroenterol. Apr 28, 2017; 23(16): 2995-3002
Published online Apr 28, 2017. doi: 10.3748/wjg.v23.i16.2995
Published online Apr 28, 2017. doi: 10.3748/wjg.v23.i16.2995
Table 1 Background characteristics of survey respondents
Parameter | n (%) | |
University hospital | 256 (78.8) | |
Practice setting | Regional/district hospital | 33 (10.1) |
Outpatient clinic | 36 (11.1) | |
Less than 25% | 183 (55.3) | |
IBD in clinic | 25% or more (IBD expert) | 148 (46.7) |
Years of practice, median (IQR, range) | 10.5 (5-20, 0.5-60) | |
Country of practice | Australia | 31 (9.1) |
Brazil | 22 (6.5) | |
Canada | 40 (11.8) | |
China | 38 (11.2) | |
France | 9 (2.6) | |
Greece | 46 (13.5) | |
Israel | 33 (9.7) | |
Italy | 19 (5.8) | |
South Korea | 20 (5.9) | |
Serbia | 10 (2.9) | |
United Kingdom | 19 (5.8) | |
United States | 53 (15.6) |
Table 2 Uni-variant and multi-variable analysis of factors for their association with prescribing combination 5-Aminosalycilates + corticosteroids to a hospitalized moderate-severe ulcerative colitis patient
Variable | Rate | Unadjusted odds ratio for prescribing combination 5ASA + CS | 95%CI | P value | Adjusted odds ratio for prescribing combination 5ASA + CS | 95%CI | P value |
Believe 5ASA are very safe | 94% | 4.20 | 1.02-17.1 | 0.045 | 2.9 | 0.4-22 | 0.3 |
Believe 5ASA are not expensive | 53% | 1.45 | 0.88-2.3 | 0.140 | 1.3 | 0.7-2.6 | 0.4 |
Believe 5ASA mode-of-action may synergize with CS | 60% | 7.30 | 4-13.3 | 0.001 | 7.9 | 3.8-17 | < 0.001 |
IBD expert | 55% | 0.63 | 0.39-1.03 | 0.070 | 0.6 | 0.3-1.2 | 0.14 |
Work in out-patient clinic setting | 11% | 3.70 | 1.3-11.1 | 0.010 | 2.7 | 0.6-12 | 0.2 |
Years of practice (odds ratio/yr) | - | - | - | - | 0.97 | 0.94-0.99 | 0.04 |
- Citation: Ben-Horin S, Andrews JM, Katsanos KH, Rieder F, Steinwurz F, Karmiris K, Cheon JH, Moran GW, Cesarini M, Stone CD, Schwartz D, Protic M, Roblin X, Roda G, Chen MH, Har-Noy O, Bernstein CN. Combination of corticosteroids and 5-aminosalicylates or corticosteroids alone for patients with moderate-severe active ulcerative colitis: A global survey of physicians' practice. World J Gastroenterol 2017; 23(16): 2995-3002
- URL: https://www.wjgnet.com/1007-9327/full/v23/i16/2995.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i16.2995